Consensus Avalo Therapeutics, Inc.

Stocks

AVTX

US05338F3064

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 12:00:28 02/10/26 am AEST			5-day change	1st Jan Change
15.11 ^USD	-1.44%		-0.95%	-14.26%

21/09	Avalo Therapeutics, Inc.(NasdaqCM:AVTX) added to S&P Global BMI Index	CI
20/08	Avalo Therapeutics Insider Sold Shares Worth $1,450,419, According to a Recent SEC Filing	MT

Evolution of the Average Target: Avalo Therapeutics, Inc.

Evolution of the Target Price: Avalo Therapeutics, Inc.

Changes in Analyst Recommendations: Avalo Therapeutics, Inc.

7fbca9dc0f0acb1ba.kHiSoVwBihfUaR0X0UzuOwfPZLJ9kX2BVPlBPUS60Nw.wjr4kR8s_yXlDSwnmASoCTG_I8tN80W2I5w7DTbRg477If2TCzH6L6BQJQ~69a20f393bf09ff7d114fc44e78c2e5c

Analysts' recommendations: Avalo Therapeutics, Inc.

13/06	Avalo Therapeutics' Lead Drug now a Cleaner Immunology Story, BofA Says	MT
12/06	BofA Initiates Avalo Therapeutics at Buy With $35 Price Target	MT
14/05	Mizuho Adjusts Price Target on Avalo Therapeutics to $45 From $39, Maintains Outperform Rating	MT
14/05	Wedbush Adjusts Price Target on Avalo Therapeutics to $34 From $40, Maintains Outperform Rating	MT
07/05	Wedbush Adjusts Price Target on Avalo Therapeutics to $40 From $29, Maintains Outperform Rating	MT
24/03	Wedbush Raises Price Target on Avalo Therapeutics to $29 From $28, Keeps Outperform Rating	MT
02/02	Guggenheim Initiates Coverage on Avalo Therapeutics With Buy Rating, $50 Price Target	MT
18/12	Mizuho Initiates Avalo Therapeutics at Outperform With $39 Price Target	MT
05/09/25	TD Cowen Initiates Avalo Therapeutics at Buy	MT
15/08/25	Cantor Fitzgerald Initiates Avalo Therapeutics at Overweight	MT
25/03/25	Stifel Initiates Avalo Therapeutics at Buy With $36 Price Target	MT
28/02/25	Piper Sandler Initiates Avalo Therapeutics at Overweight With $48 Price Target	MT
21/02/25	Wedbush Initiates Avalo Therapeutics With Outperform Rating, $18 Price Target	MT
19/12/24	BTIG Research Initiates Avalo Therapeutics With Buy Rating, $40 Price Target	MT
24/10/24	HC Wainwright Initiates Avalo Therapeutics at Neutral	MT
16/04/24	Oppenheimer Upgrades Avalo Therapeutics to Outperform From Perform, Price Target is $35	MT
27/06/23	Oppenheimer Downgrades Avalo Therapeutics to Perform From Outperform, Removes $10 Price Target	MT
27/06/23	Avalo Therapeutics Downgraded by RBC to Sector Perform From Outperform, Price Target Cut to $0.75 From $9, Speculative Risk Kept	MT
10/05/23	RBC Cuts Price Target on Avalo Therapeutics to $9 From $17, Maintains Outperform Rating, Speculative Risk Qualifier	MT
09/02/23	Jefferies Downgrades Avalo Therapeutics to Underperform From Hold, Lowers Price Target to $3 From $4.50	MT
10/11/22	Oppenheimer Adjusts Avalo Therapeutics Price Target to $10 From $17, Maintains Outperform Rating	MT
09/08/22	Oppenheimer Adjusts Avalo Therapeutics Price Target to $17 From $5, Maintains Outperform Rating	MT
05/08/22	RBC Cuts Price Target on Avalo Therapeutics to $17 From $21, Maintains Outperform Rating, Speculative Risk Qualifier	MT
11/07/22	RBC Cuts Price Target on Avalo Therapeutics to $21 From $24 After 1-for-12 Reverse Stock Split; Outperform, Speculative Risk Kept	MT
06/05/22	RBC Halves Price Target on Avalo Therapeutics to $2 From $4, Noting 'Early Stage Risk With Minimal Safeguards,' Keeps Outperform-Speculative Risk Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	AVALO THERAPEUTICS, INC.					+187.56%
	WUXI APPTEC CO., LTD.					+11.79%
	ARGENX SE					+21.92%
	LONZA GROUP AG					+19.64%
	IQVIA HOLDINGS INC.					+7.4%
	REVOLUTION MEDICINES, INC.					+25.43%
	BEONE MEDICINES AG					+18.27%
	CELLTRION, INC.					+50.7%
	WUXI BIOLOGICS (CAYMAN) INC.					+3.91%
	INSMED INCORPORATED					+73.24%
	Average					+41.99%
	Weighted average by Cap.					+22.54%